Maximum Dose of Biotin
There is no established upper limit (UL) for biotin toxicity, and doses up to 200 mg/day IV for 2-3 weeks have been safely used in deficient patients, though the evidence documents safety for oral and IV pharmacological doses up to 5 mg/day for prolonged periods without adverse effects. 1
Safety Profile Based on Clinical Evidence
The 2022 ESPEN Micronutrient Guideline explicitly states that biotin toxicity is unlikely and no upper limit has been established 1. This represents the most authoritative guidance available on biotin dosing limits.
Documented Safe Doses by Clinical Context:
Standard supplementation:
- Enteral nutrition: 30 μg/day minimum (Grade B recommendation) 1
- Parenteral nutrition: 60 μg/day (Grade B recommendation) 1
- Breastfeeding mothers: 35 μg/day minimum 1
Therapeutic doses for deficiency:
- Malabsorption/short bowel: up to 10 mg/day orally 1
- Severe deficiency (PN-dependent): up to 200 mg/day IV for 2-3 weeks 1
- Biotinidase deficiency: 5-20 mg daily (pharmacological doses) 2
High-dose therapeutic trials:
- Multiple sclerosis studies: 300 mg/day orally for 12-15 months showed no toxicity 3, 4
- Neuropathy study: 300 mg/day (100 mg three times daily) for up to 52 weeks was well-tolerated 5
Toxicology Data
A 2021 preclinical study established a no-observed-adverse-effect-level (NOAEL) of 600 mg magnesium biotinate/kg/day in rats, which equates to approximately 39 grams of biotin per day for a 70 kg human 6. This represents roughly 1.3 million times the recommended daily allowance and 3,900 times typical supplement levels of 10 mg/day.
Critical Caveat: Laboratory Test Interference
The most significant concern with high-dose biotin is not toxicity but laboratory test interference. High-certainty evidence shows that 4.7% of patients taking high-dose biotin (300 mg/day) experienced laboratory test interference, particularly affecting streptavidin-biotin immunoassays 4. This can lead to:
- Falsely elevated or decreased thyroid hormone measurements
- Incorrect troponin results (potentially masking myocardial infarction)
- Erroneous vitamin D, hormone, and other immunoassay results
Practical recommendation: Patients taking biotin supplements >300 μg/day should discontinue supplementation at least 48-72 hours before laboratory testing, and clinicians should be alerted to biotin use when ordering immunoassays.
Clinical Context for Dosing
For general supplementation without deficiency: Standard multivitamin doses (30-100 μg/day) are appropriate and safe.
For documented biotinidase deficiency: 5-20 mg/day is the established therapeutic range with excellent long-term outcomes 2.
For investigational high-dose therapy (e.g., progressive MS, neuropathies): Doses of 300 mg/day have been used safely for up to 15 months, though efficacy remains questionable 5, 3, 4.
For pregnancy: Requirements may be higher than standard recommendations, with studies using 300 μg/day showing benefit 1.
The evidence consistently demonstrates that biotin has an exceptionally wide safety margin, with no established maximum dose from a toxicity standpoint. However, doses exceeding 300 μg/day warrant consideration of laboratory test interference as the primary clinical concern rather than direct toxicity.